Quick Overview: Andrew Yee, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of GPRC5D ... In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of BCMA-

Beyond Karmma 2 Agents Targeting - Detailed Overview & Context

Andrew Yee, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of GPRC5D ... In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of BCMA- A roundtable discussion, moderated by Thomas Martin, MD, Blood Cancers Today Associate Editor, of the University of California, ... Loss of B-cell maturation antigen (BCMA) poses a large challenge, with many newer therapies having this Co-Chairs, Thomas G. Martin, III, MD, and Krina Patel, MD, MSc, discuss multiple myeloma in this CME activity titled “Hitting the ...

Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, presents the results of one arm of the Phase Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, talks on the sequencing of B-cell ... Idecabtagene vicleucel (ide-cel; bb2121), a BCMA- Prof. Mohamad Mohty Prof. Marc Raab Prof. Maria-Victoria Mateos June MMSM & crew ⏳The wait is over! Join Dr. Joseph Mikhael, Dr. Nina Shah, and Dr. Surbhi Sidana for Broadcast ... On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into ...

Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, explains where BCMA- Michel Delforge, MD, PhD, of the University of Leuven, Leuven, Belgium, discusses results from the During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to María-Victoria ... Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA ... Watch the full course and our most up-to-date content here: Create a free account to track ... In this video, Paula Rodríguez-Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, shares some updated results from ...

Photo Gallery

Beyond KarMMa-2: agents targeting BCMA in MM
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma
Dosing Considerations, Care Team Handoffs for Bispecific Agents
Beyond BCMA: GPRC5D & FcRH5
Hitting the BCMA Target in Multiple Myeloma
KarMMA-2 cohort 2b update: ide-cel for transplant-ineligible patients with high-risk myeloma
Sequencing BCMA-targeted therapies in myeloma
ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results
Novel agents in myeloma: different targets and mechanisms of action
Efficacy & Safety of Approved & Emerging BCMA-directed Therapies in Multiple Myeloma
Novel agents in the post-BCMA space in myeloma
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored